Literature DB >> 29756366

Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.

Daisuke Taniguchi1, Taku Hatano1, Koji Kamagata2, Ayami Okuzumi1, Yutaka Oji1, Akio Mori1, Masaaki Hori2, Shigeki Aoki2, Nobutaka Hattori1.   

Abstract

Background Nigral degeneration patterns differ between PSP and PD. However, the relationship between nigral degeneration and midbrain atrophy in PSP remains unclear. Objective We analyzed differences and relationships between nigral degeneration and midbrain atrophy in PSP and PD. Methods Neuromelanin-sensitive MRI and midbrain volumetry were performed in 11 PSP patients, 24 PD patients, and 10 controls to measure the neuromelanin-sensitive SNpc area and midbrain volume. Results The neuromelanin-sensitive SNpc area and midbrain volume were significantly smaller in PSP patients compared with PD patients and controls. Motor deficits were inversely correlated with neuromelanin-sensitive SNpc area in PD, but not PSP patients. There was no significant correlation between neuromelanin-sensitive SNpc area and midbrain volume in either disease group. Midbrain volumetry discriminated PSP from PD. Diagnostic accuracy was improved when neuromelanin-sensitive MRI analysis was added. Conclusions Neuromelanin-sensitive MRI and midbrain volumetry may reflect the clinical and pathological characteristics of PSP and PD. Combining neuromelanin-sensitive MRI and midbrain volumetry may be useful for differentiating PSP from PD.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; midbrain; neuromelanin; progressive supranuclear palsy; volumetry

Mesh:

Substances:

Year:  2018        PMID: 29756366     DOI: 10.1002/mds.27365

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

1.  Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis.

Authors:  Se Jin Cho; Yun Jung Bae; Jong-Min Kim; Donghyun Kim; Sung Hyun Baik; Leonard Sunwoo; Byung Se Choi; Jae Hyoung Kim
Journal:  Eur Radiol       Date:  2020-09-04       Impact factor: 5.315

2.  The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis.

Authors:  Xiangming Wang; Yuehui Zhang; Chen Zhu; Guangzong Li; Jie Kang; Fang Chen; Ling Yang
Journal:  Neurol Sci       Date:  2019-08-07       Impact factor: 3.307

Review 3.  Structural Imaging in Parkinson's Disease: New Developments.

Authors:  Stéphane Prange; Elise Metereau; Stéphane Thobois
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-18       Impact factor: 5.081

Review 4.  Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms.

Authors:  Cecilia Peralta; Antonio P Strafella; Thilo van Eimeren; Roberto Ceravolo; Klaus Seppi; Valtteri Kaasinen; Julieta E Arena; Stephane Lehericy
Journal:  Mov Disord Clin Pract       Date:  2021-11-15

Review 5.  MRI biomarkers of motor and non-motor symptoms in Parkinson's disease.

Authors:  Sephira G Ryman; Kathleen L Poston
Journal:  Parkinsonism Relat Disord       Date:  2019-10-10       Impact factor: 4.891

6.  Neuronuclear and Neuromelanin-Sensitive Imaging for Acquired Hepatocerebral Degeneration with Parkinsonism.

Authors:  Takashi Ogawa; Kotaro Ogaki; Yuko Mori; Hikaru Kamo; Akira Uchiyama; Koji Kamagata; Masanori Nagaoka; Nobutaka Hattori
Journal:  Mov Disord Clin Pract       Date:  2021-03-26

7.  Early-stage Parkinson's disease: Abnormal nigrosome 1 and 2 revealed by a voxelwise analysis of neuromelanin-sensitive MRI.

Authors:  Young Hee Sung; Young Noh; Eung Yeop Kim
Journal:  Hum Brain Mapp       Date:  2021-03-10       Impact factor: 5.038

8.  Short-echo-time magnitude image derived from quantitative susceptibility mapping could resemble neuromelanin-sensitive MRI image in substantia nigra.

Authors:  Xue Ling Liu; Li Qin Yang; Feng Tao Liu; Pu-Yeh Wu; Yong Zhang; Han Zhuang; Yong Hong Shi; Jian Wang; Dao Ying Geng; Yu Xin Li
Journal:  BMC Neurol       Date:  2020-06-30       Impact factor: 2.474

9.  Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease?

Authors:  A Okuzumi; T Hatano; K Kamagata; M Hori; A Mori; Y Oji; D Taniguchi; K Daida; Y Shimo; N Yanagisawa; S Nojiri; S Aoki; N Hattori
Journal:  Eur J Neurol       Date:  2019-06-24       Impact factor: 6.089

10.  Semi-Automatic Signature-Based Segmentation Method for Quantification of Neuromelanin in Substantia Nigra.

Authors:  Gašper Zupan; Dušan Šuput; Zvezdan Pirtošek; Andrej Vovk
Journal:  Brain Sci       Date:  2019-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.